AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01397162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate
Study NCT01397162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI
Study NCT01397162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903
Study NCT03022136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold sensation method
Description: Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
Study NCT02975518 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Administration of radio labelled endothelial outgrowth cells
Description: Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
Study NCT02975518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of radio labelled endothelial outgrowth cells
Description: Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
Study NCT04511546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPET Prototype Scan
Description: Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
Study NCT00962910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFF evidence based pathway
Description: A care pathway, as complex intervention, will be implemented.
Study NCT03959943 — intervention group
Intervention type: PROCEDURE
Intervention: Sensory nerve coaptation
Description: A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
Study NCT03980041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 (40mg QD) administered orally in 28-day cycles
Study NCT03980041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
Study NCT03980041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
Study NCT03980041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Placebo administered orally in 28-day cycles
Study NCT02793921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Aerobic Exercise Intervention
Description: The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
Study NCT00808860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GP group
Description: Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
Study NCT00808860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
Study NCT03777774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive Redon subgaleal drains
Description: Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
Study NCT03777774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Redon subgaleal drains
Description: Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
Study NCT03777774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Redon subgaleal drains
Description: A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
Study NCT00957554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan/amlodipine
Description: Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
Study NCT00957554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
Study NCT00354744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV
Study NCT03076684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-fructose diet
Description: Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
Study NCT03076684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Subjects in the drug arm will take the drug allopurinol daily.
Study NCT00354744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV
Study NCT00354744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV
Study NCT00354744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV
Study NCT00354744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV
Study NCT00354744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV
Study NCT00354744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV
Study NCT00354744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Resection of the primary tumor with a surrounding envelope of normal tissue
Study NCT00354744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
Study NCT00354744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously.
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy.
Study NCT02176395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
Study NCT02176395 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
Study NCT02176395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy medication
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy medication
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy medication
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Chemotherapy medication
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Chemotherapy medication
Study NCT03539328 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: Chemotherapy medication
Study NCT04479930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Care Web-Based App (HappyAir App)
Description: The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
Study NCT01890473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT00983437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Study NCT00936156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (carboplatin, etoposide, thiotepa)
Description: Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
Study NCT01945281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Study NCT01945281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B Deoxycholate
Study NCT03196726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Description: Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
Study NCT03379012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecanoate and sunitinib or pazopanib
Description: Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
Study NCT03379012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate and sunitinib or pazopanib
Description: Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
Study NCT02225444 — intervention group
Intervention type: OTHER
Intervention: OsteoAMP
Description: OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
Study NCT00264849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
Study NCT00264849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized asthma therapy
Description: Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
Study NCT00264849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized asthma therapy
Description: Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
Study NCT04253041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of Instagram Exposure on Lifestyle Satisfaction
Description: Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
Study NCT03196726 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard management based on Clinical Practice Guideline
Description: Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
Study NCT03196726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard management based on Clinical Practice Guideline
Description: Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
Study NCT00691314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation (Wingspan, Coroflex, and TiTAN2)
Description: Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1
Study NCT00691314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
Study NCT02949206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 Factor Prothrombin Complex Concentrate (PCC)
Description: Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
Study NCT03270150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: BTL-899
Study NCT02765178 — intervention group
Intervention type: OTHER
Intervention: Children's Motivation Scale
Description: A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
Study NCT02765178 — intervention group
Intervention type: OTHER
Intervention: Yale Global Tic Severity Scale (YGTSS)
Description: Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
Study NCT02765178 — intervention group
Intervention type: OTHER
Intervention: Studies Depression Scale for Children (CES-DC)
Description: Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents
Study NCT02765178 — intervention group
Intervention type: OTHER
Intervention: Gilles de la Tourette Syndrome Quality Of Life scale
Description: Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
Study NCT02765178 — intervention group
Intervention type: OTHER
Intervention: Demographic Data
Description: Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
Study NCT04338516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossix™ Bone
Description: a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
Study NCT04338516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss® Collagen
Description: 90% bovine derived xenograft granules and 10% porcine collagen
Study NCT02488616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5-day intervention with single-hormone closed-loop strategy
Description: A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days.
Study NCT02013752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal protection device.
Description: A device used to reduce perineal tears during delivery of the baby.